Importance of multigene panel test in patients with consanguineous marriage and family history of breast cancer.
breast cancer
consanguineous marriage
multigene testing
pathogenic variant
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
25
07
2021
accepted:
06
01
2022
entrez:
9
3
2022
pubmed:
10
3
2022
medline:
10
3
2022
Statut:
ppublish
Résumé
Next-generation sequencing (NGS) technology is used to evaluate hereditary cancer risks of patients worldwide; however, information concerning the germline multigene mutational spectrum among patients with breast cancer (BC) with consanguineous marriage (CM) is limited. Therefore, this prospective study aimed to determine the molecular characteristics of patients with BC who were tested with multigene hereditary cancer predisposition NGS panel and to show the effect of CM on cancer-related genes. Patients with BC with or without CM and family history (FH) of BC treated in our breast center were selected according to The National Comprehensive Cancer Network (NCCN) criteria for hereditary BC. In these patients, the analysis of a panel of 33 genes involved in hereditary cancer predisposition was performed after genetic counseling by using NGS. The pathogenic variant (PV) and the variant of uncertain significance (VUS) were found to be 15.8 and 47.4%, respectively. PVs were identified in 10/33 genes in 34 patients; 38.2% in BRCA1/2 genes; 6, 24, and 14% in other high, moderate and low-risk genes, respectively. The CM rate was 17.7% among the 215 patients with BC. The PV rate was 13.2% in patients with CM and 16.4% in patients without CM (P=0.80). When PV and VUS were evaluated together, the PV+VUS ratio was significantly higher in patients with CM and FH of BC than patients without CM and FH of BC (88.2 vs. 63.3%, P=0.045). Analysis of multigene panel provided 9.76% additional PVs in moderate/low-risk genes. The PV rate was similar in patients with BC with or without CM. A high PV+VUS ratio in patients with CM and FH of BC suggests that genes whose importance are unknown are likely to be pathogenic genes later.
Identifiants
pubmed: 35261632
doi: 10.3892/ol.2022.13238
pii: OL-23-04-13238
pmc: PMC8855161
doi:
Types de publication
Journal Article
Langues
eng
Pagination
118Informations de copyright
Copyright: © Ozmen et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Cancer. 2012 Nov 1;118(21):5210-6
pubmed: 22544547
Asian Pac J Cancer Prev. 2015;16(9):4051-5
pubmed: 25987085
Gastroenterology. 2015 Sep;149(3):604-13.e20
pubmed: 25980754
Am J Surg. 2021 Jun;221(6):1159-1163
pubmed: 33849710
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Nat Genet. 2007 Feb;39(2):162-4
pubmed: 17200671
Breast Cancer Res Treat. 2014 Jun;145(3):625-34
pubmed: 24825132
Am J Hum Genet. 1991 Feb;48(2):232-42
pubmed: 1990835
MDM Policy Pract. 2019 Feb 01;4(1):2381468318821103
pubmed: 30746499
J Community Genet. 2012 Jul;3(3):185-92
pubmed: 22109912
Fam Cancer. 2013 Mar;12(1):75-81
pubmed: 23131904
JAMA. 2006 Mar 22;295(12):1379-88
pubmed: 16551709
J Genet Couns. 2013 Dec;22(6):858-64
pubmed: 24046181
Hum Mutat. 2016 Apr;37(4):331-6
pubmed: 26777316
Cancer Biol Med. 2016 Mar;13(1):55-67
pubmed: 27144062
JAMA. 2010 Sep 1;304(9):967-75
pubmed: 20810374
Hum Hered. 2014;77(1-4):6-9
pubmed: 25060264
Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2963-2972
pubmed: 30362333
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Genet Med. 2018 Mar;20(3):346-350
pubmed: 29215655
Ann Genet. 2004 Apr-Jun;47(2):129-38
pubmed: 15183745
J Clin Oncol. 2019 Feb 20;37(6):453-460
pubmed: 30526229
Int J Cancer. 2017 Jul 1;141(1):129-142
pubmed: 28294317
J Med Genet. 2006 Sep;43(9):e49
pubmed: 16950820
Eur J Breast Health. 2018 Apr 01;14(2):93-99
pubmed: 29774317
BMC Cancer. 2008 May 26;8:146
pubmed: 18501021
Cancer Cell. 2007 Feb;11(2):103-5
pubmed: 17292821
Breast Cancer Res Treat. 2011 Apr;126(3):705-16
pubmed: 20859677
Genet Med. 2020 Feb;22(2):407-415
pubmed: 31406321
BMC Cancer. 2019 Jun 3;19(1):535
pubmed: 31159747
Proc Natl Acad Sci U S A. 1988 May;85(9):3044-8
pubmed: 3362861
Int J Cancer. 2021 Jan 15;148(2):285-295
pubmed: 32658311
Hum Mutat. 2017 Jul;38(7):889-897
pubmed: 28449315
Science. 2002 Jul 26;297(5581):606-9
pubmed: 12065746
Science. 2014 Mar 28;343(6178):1466-70
pubmed: 24675953
JAMA Surg. 2017 Jun 1;152(6):589-594
pubmed: 28423155
Gynecol Oncol. 2010 Oct;119(1):131-5
pubmed: 20638108
Nat Genet. 2005 Sep;37(9):934-5
pubmed: 16116423